Key considerations for RhoGAM administration protocol

The RhoGAM protocol is designed to provide protection during the periods when fetomaternal hemorrhage is most likely to occur.2,4

Before administration, confirm the patient's Rh-negative status and verify a negative antibody screen to rule out pre-existing anti-D sensitization. If sensitization has already occurred, RhoGAM will not be effective.2

RhoGAM is administered intramuscularly (IM), in accordance with institutional protocols for intramuscular injections.2

When should RhoGAM be administered?

RhoGAM administration timing and dose are critical to effective prophylaxis, particularly during pregnancy.1 The following sections summarize the key timing and dosing considerations.

Routine antenatal prophylaxis

For unsensitized Rh-negative pregnant women, a single dose of 300 is administered at 26-28 weeks of gestation.2

Postpartum administration

After delivery, if the newborn is determined to be Rh-positive, a second dose of 300 μg (1500 IU) of RhoGAM should be administered to the Rh-negative mother within 72 hours of delivery.2

Administration following potentially sensitizing events

In addition to routine antenatal and postpartum administration, RhoGAM is indicated after any event that may cause fetomaternal hemorrhage. These include, but are not limited to2:

  • Maternal or fetal bleeding during pregnancy from certain conditions
  • Actual or threatened pregnancy loss at any stage
  • Ectopic pregnancy
  • Amniocentesis
  • Chorionic villus sampling (CVS)
  • Manipulative procedures
  • Other obstetrical trauma

Monitoring after administration

After RhoGAM is administered, patients should be monitored for any adverse reactions, although most side effects are mild. Common reactions may include tenderness or swelling at the injection site or a mild fever. Rare but serious allergic reactions are possible and require immediate medical attention.2

Effective anti-D administration remains a cornerstone of modern obstetrical practice. By preventing Rh sensitization in Rh-negative mothers, it helps safeguard future pregnancies and reduces the risk of HDFN.3 By understanding and meticulously following the RhoGAM administration guidelines and protocols for timing and dosing, healthcare professionals can ensure that this preventative measure is delivered safely and effectively.